Drug Profile
Research programme: peptide therapeutics - Boehringer Ingelheim/Gubra
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Gubra
- Class Obesity therapies; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Obesity in Denmark
- 28 Oct 2021 No recent reports of development identified for research development in Obesity in Germany
- 01 Mar 2021 Boehringer Ingelheim and Gubra agree to co-develop peptide therapeutics for Obesity